Nk cells or t cells expressing hematopoietic growth factor receptors and methods of use
AssigneeThe United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsRichard W. Childs, David S.J. Allan, Chantiya Chanswangphuwana
Life of this patent
Estimating the term…
Abstract
Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some embodiments, the NK cells or T cells express a thrombopoietin receptor or an erythropoietin receptor. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.
Claims14
A method of treating a subject with cancer, comprising:
- administering a modified NK cell or T cell expressing a heterologous erythropoietin receptor (EPOR) protein to the subject;
- and
- administering an EPOR agonist to the subject.
Dependencies are inferred from the claim text.